Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.

@article{Versiani1990TolerabilityOM,
  title={Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.},
  author={M{\'a}rcio C Versiani and Antonio Egidio Nardi and Ivan Figueira and M. Stabl},
  journal={Acta psychiatrica Scandinavica. Supplementum},
  year={1990},
  volume={360},
  pages={24-8}
}
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Pooled data from these studies, comprising 1656 patients, as well as the consideration of individual trials, show that moclobemide is far better tolerated than the TCAs. Its side effects mainly comprise mild degrees of nausea and dizziness at the beginning of treatment in a small proportion of patients. Age and sex… CONTINUE READING